Pluristem jumps as FDA lifts suspension of Phase II drug trial

The FDA has lifted a clinical hold on the Phase II trials of Pluristem's (PSTI +9.3%) placenta-based IND 15038 cell treatment for intermittent claudication, which occurs when there is a reduction in the flow of blood to the leg muscles during exercise, causing pain.

The agency had halted the testing in June following "a serious allergic reaction" in one patient. Pluristem had suspended trials in Germany as well. (PR)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs